Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 04696b)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Daunorubicin and cytarabine liposome is a synergistic fixed-ratio liposomal formulation of the anthracycline daunorubicin and the antimetabolite cytarabine. Encapsulated in a 1:5 molar ratio, this formulation is designed to optimize the delivery of these two cytotoxic agents to bone marrow blasts while minimizing systemic exposure and toxicity. Daunorubicin acts by intercalating DNA and inhibiting topoisomerase II, while cytarabine is a pyrimidine analog that inhibits DNA polymerase and DNA synthesis. The liposomal delivery system extends the plasma half-life of the drugs and facilitates their preferential uptake by leukemic cells. It is primarily indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). CSPC Zhongnuo Pharmaceutical is developing a version of this liposomal combination in China, currently in Phase 3 clinical trials for high-risk secondary AML.
- Brand names
- Vyxeos
- Other names
- CPX351CPX-351CPX 351liposomal daunorubicin-cytarabine柔红霉素阿糖胞苷脂质体
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 04696b).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 04696b).